Min Kim, Kyoung Hwa Ha, Junyoung Lee, Sangshin Park, Kyeong Seok Oh, Dae-Hwan Bae, Ju Hee Lee, Sang Min Kim, Woong Gil Choi, Kyung-Kuk Hwang, Dong-Woon Kim, Myeong-Chan Cho, Dae Jung Kim, Jang-Whan Bae
BACKGROUND AND OBJECTIVES: Accumulating evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce adverse cardiovascular outcomes. However, whether SGLT2i, compared with other antidiabetic drugs, reduce the new development of atrial fibrillation (AF) is unclear. In this study, we compared SGLT2i with dipeptidyl peptidase-4 inhibitors (DPP-4is) in terms of reduction in the risk of AF in individuals with type 2 diabetes. METHODS: We included 42,786 propensity score-matched pairs of SGLT2i and DPP-4i users without previous AF diagnosis using the Korean National Health Insurance Service database between May 1, 2016, and December 31, 2018...
March 13, 2024: Korean Circulation Journal